Stock CYXO CYXONE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cyxone AB

Equities

CYXO

SE0007815428

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:05:53 2024-04-26 am EDT 		5-day change 1st Jan Change
0.0928 SEK -4.33% Intraday chart for Cyxone AB +6.91% -7.57%
Apr. 22 Sweden's Cyxone Appoints New CEO MT
Apr. 22 Cyxone AB Announces Chief Executive Officer Changes CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 96.08 205.6 246.2 111.9 50.31 9.884 20.04 -
Enterprise Value (EV) 1 57.36 143.9 189.8 82.59 50.31 9.884 19.04 -20.96
P/E ratio - - - - -1.16 x -0.46 x -0.71 x -0.52 x
Yield - - - - - - - -
Capitalization / Revenue 96,079 x 5,712 x - 6,219 x - - - -
EV / Revenue 57,363 x 3,997 x - 4,588 x - - - -
EV / EBITDA -3.79 x -4.33 x -4.03 x -1.91 x - - -0.73 x 0.6 x
EV / FCF -1.32 x -3.97 x -4.21 x -1.87 x - - -0.73 x 0.6 x
FCF Yield -75.8% -25.2% -23.7% -53.5% - - -137% 167%
Price to Book 1.36 x 2.87 x 3.67 x 2.75 x - - 0.93 x 0.34 x
Nbr of stocks (in thousands) 37,458 49,080 58,063 63,677 98,445 98,445 215,926 -
Reference price 2 2.565 4.190 4.240 1.758 0.5110 0.1004 0.0928 0.0928
Announcement Date 2/14/19 2/14/20 2/12/21 2/22/22 2/17/23 2/27/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 0.001 0.036 - 0.018 - - - -
EBITDA 1 -15.12 -33.24 -47.08 -43.23 - - -26 -35
EBIT 1 -15.43 -35.03 -48.88 -45.03 - - -28 -38
Operating Margin -1,543,400% -97,305.56% - -250,155.56% - - - -
Earnings before Tax (EBT) 1 - - - - - - -28 -38
Net income 1 - - - - -42.47 -22.99 -28 -38
Net margin - - - - - - - -
EPS 2 - - - - -0.4400 -0.2200 -0.1300 -0.1800
Free Cash Flow 1 -43.49 -36.22 -45.06 -44.14 - - -26 -35
FCF margin -4,349,200% -100,602.78% - -245,238.89% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/14/19 2/14/20 2/12/21 2/22/22 2/17/23 2/27/24 - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 38.7 61.8 56.3 29.4 - - 1 41
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -43.5 -36.2 -45.1 -44.1 - - -26 -35
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.880 1.460 1.160 0.6400 - - 0.1000 0.2700
Cash Flow per Share - - - - - - - -
Capex 1 29.1 0.99 0.18 0.89 - - - -
Capex / Sales 2,914,800% 2,752.78% - 4,955.56% - - - -
Announcement Date 2/14/19 2/14/20 2/12/21 2/22/22 2/17/23 2/27/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
CYXONE AB Stock Cyxone AB
-7.57% 1.83M
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CYXO Stock
  4. Financials Cyxone AB